Inicio
Hospital Practice
|
Tipo de obra :
Autre
Naturaleza de la obra :
Oeuvre
|
Documentos disponibles con este título uniforme (2)
Clasificado(s) por (Año de edición descendente) Refinar búsquedaComparative effectiveness of human hematin and heme arginate in themanagement of porphyria attacks: an observational study across three hospitals inColombia / Andrés Felipe Valencia Quintero ; Natalia Andrea Rojas Henao ; Enyd Estefanía Rave Builes ; Nieto López, Emmanuel Salvador
Título : Comparative effectiveness of human hematin and heme arginate in themanagement of porphyria attacks: an observational study across three hospitals inColombia Tipo de documento : documento electrónico Autores : Andrés Felipe Valencia Quintero, Autor ; Natalia Andrea Rojas Henao, Autor ; Enyd Estefanía Rave Builes, Autor ; Nieto López, Emmanuel Salvador, Autor Fecha de publicación : 2025 Títulos uniformes : Hospital Practice Idioma : Inglés (eng) Palabras clave : Porphyria hematin heme arginate treatment outcome Drug effects Resumen : Background: Porphyria is an orphan disease classified as a genetic disorder caused by a partial or high-grade deficiency of enzymes involved in the synthesis of heme, an essential component of hemoglobin.This deficiency results in the accumulation of porphyrins (ALAS1 and PBG), intermediates in the hememetabolic pathway. This accumulation triggers porphyria attacks. In Colombia the Heme Arginate andHuman Hematin are the therapeutics alternatives for the management of porphyria AttacksObjective: To evaluate the comparative effectiveness of heme arginate versus human hemin fortreating porphyria attacks in hospitalized patients across three institutions in Medellin, Colombia.Methods: An observational and analytical study was conducted to compare the outcomes of treatmentwith human hematin versus heme arginate in clinical episodes of patients diagnosed with porphyriabetween 2015–2021.Results: In episodes treated with heme arginate (ArgH), 75% achieved pain control or reduction, 41.6%showed a reduction in opioid dosage, and 88.8% achieved resolution of the Porphyria attack. Forepisodes treated with human hematin (HH), 85.3% achieved pain control or reduction, 53.6% showeda reduction in opioid dosage, and 90.2% achieved resolution of the attack. When evaluating theeffectiveness of both treatments, no statistically significant differences were observed across thethree predefined effectiveness outcomes of the study.Conclusions: This study provides a comparative evaluation of heme arginate (ArgH) and humanhematin (HH) in the management of Porphyria attacks, demonstrating that both treatments are similarlyeffective in achieving pain control, reducing opioid use, and resolving clinical attacks. Mención de responsabilidad : Natalia A Rojas Henao, Andres Felipe Valencia, Emmanuel Salvador Nieto López DOI (Digital Object Identifier) : 10.1080/21548331.2025.2520743 Derechos de uso : CC BY-NC-ND En línea : https://www.tandfonline.com/doi/full/10.1080/21548331.2025.2520743#abstract Enlace permanente : https://hospitalpablotobon.cloudbiteca.com/pmb/opac_css/index.php?lvl=notice_dis Comparative effectiveness of human hematin and heme arginate in themanagement of porphyria attacks: an observational study across three hospitals inColombia [documento electrónico] / Andrés Felipe Valencia Quintero, Autor ; Natalia Andrea Rojas Henao, Autor ; Enyd Estefanía Rave Builes, Autor ; Nieto López, Emmanuel Salvador, Autor . - 2025.
Obra : Hospital Practice
Idioma : Inglés (eng)
Palabras clave : Porphyria hematin heme arginate treatment outcome Drug effects Resumen : Background: Porphyria is an orphan disease classified as a genetic disorder caused by a partial or high-grade deficiency of enzymes involved in the synthesis of heme, an essential component of hemoglobin.This deficiency results in the accumulation of porphyrins (ALAS1 and PBG), intermediates in the hememetabolic pathway. This accumulation triggers porphyria attacks. In Colombia the Heme Arginate andHuman Hematin are the therapeutics alternatives for the management of porphyria AttacksObjective: To evaluate the comparative effectiveness of heme arginate versus human hemin fortreating porphyria attacks in hospitalized patients across three institutions in Medellin, Colombia.Methods: An observational and analytical study was conducted to compare the outcomes of treatmentwith human hematin versus heme arginate in clinical episodes of patients diagnosed with porphyriabetween 2015–2021.Results: In episodes treated with heme arginate (ArgH), 75% achieved pain control or reduction, 41.6%showed a reduction in opioid dosage, and 88.8% achieved resolution of the Porphyria attack. Forepisodes treated with human hematin (HH), 85.3% achieved pain control or reduction, 53.6% showeda reduction in opioid dosage, and 90.2% achieved resolution of the attack. When evaluating theeffectiveness of both treatments, no statistically significant differences were observed across thethree predefined effectiveness outcomes of the study.Conclusions: This study provides a comparative evaluation of heme arginate (ArgH) and humanhematin (HH) in the management of Porphyria attacks, demonstrating that both treatments are similarlyeffective in achieving pain control, reducing opioid use, and resolving clinical attacks. Mención de responsabilidad : Natalia A Rojas Henao, Andres Felipe Valencia, Emmanuel Salvador Nieto López DOI (Digital Object Identifier) : 10.1080/21548331.2025.2520743 Derechos de uso : CC BY-NC-ND En línea : https://www.tandfonline.com/doi/full/10.1080/21548331.2025.2520743#abstract Enlace permanente : https://hospitalpablotobon.cloudbiteca.com/pmb/opac_css/index.php?lvl=notice_dis Reserva
Reservar este documento
Ejemplares(1)
Código de barras Número de Ubicación Tipo de medio Ubicación Sección Estado DD002385 AC-2025-068 Archivo digital Producción Científica Artículos científicos Disponible
Título : Direct costs of severe hypoglycemia events in individuals with diabetes mellitus: a perspective from the Colombian health system - a single-center study Tipo de documento : documento electrónico Autores : Michael Andrés García Rivera, Autor ; Natalia Andrea Rojas Henao, Autor ; Hernández Herrera, Ana C., Autor ; Juliana Díaz Giraldo, Autor ; Carlos Esteban Builes Montaño, Autor Fecha de publicación : 2025 Títulos uniformes : Hospital Practice Idioma : Inglés (eng) Palabras clave : Diabetes mellitus; Latin America; cost of illness; diabetes complications; hypoglycemia Resumen : Background and aims: Diabetes mellitus is one of the more prevalent chronic diseases globally, and healthcare expenditures for diabetes care are on the rise. Intensive diabetes treatment has been associated with reducing the risk of chronic complications. However, hypoglycemia, the most common adverse effect, poses a significant risk to individuals' lives and is linked to high costs for healthcare systems. Methods: We conducted a retrospective cross-sectional study to determine direct costs by identifying emergency room visits due to hypoglycemia events using diagnostic codes during January 2017 to June 2019. Direct costs were calculated using billed data from the payer and information on outpatient treatment regimens. Differences in median costs were estimated based on length of stay and type of outpatient treatment. Results: Data from 101 patients and the same number of events were included. Women represented (62.4%) of the patients, the median age was 70 (IQR 59.5-80). Blood glucose levels at admission ranged from 12 mg/dL to 67 mg/dL. Most patients were on insulin for outpatient treatment. The median cost of care per hypoglycemia episode was US $345.35 (IQR US $202-727.8), and the cost per episode was higher in patients treated with regimens that included sulfonylureas. Conclusions: The management of patients admitted to the emergency department with a diagnosis of hypoglycemia places a significant burden on the Colombian healthcare system, primarily due to the associated hospitalization costs. Patients treated with regimens that included sulfonylureas incurred higher costs per episode. Prevention, patient education, and individualized treatment approaches could help alleviate the burden of hypoglycemia on both patients and the healthcare system. Mención de responsabilidad : Rojas-Henao, Natalia A; Garcia-Rivera, Michael; Hernandez-Herrera, Ana C.; Díaz-Giraldo, Juliana; Builes-Montaño, Carlos E. Referencia : Hosp Pract (1995). 2025 Feb;53(1):2439775 DOI (Digital Object Identifier) : 10.1080/21548331.2024.2439775 PMID : 39648816 Derechos de uso : CC BY-NC-ND En línea : https://pubmed.ncbi.nlm.nih.gov/39648816/ Enlace permanente : https://hospitalpablotobon.cloudbiteca.com/pmb/opac_css/index.php?lvl=notice_dis Direct costs of severe hypoglycemia events in individuals with diabetes mellitus: a perspective from the Colombian health system - a single-center study [documento electrónico] / Michael Andrés García Rivera, Autor ; Natalia Andrea Rojas Henao, Autor ; Hernández Herrera, Ana C., Autor ; Juliana Díaz Giraldo, Autor ; Carlos Esteban Builes Montaño, Autor . - 2025.
Obra : Hospital Practice
Idioma : Inglés (eng)
Palabras clave : Diabetes mellitus; Latin America; cost of illness; diabetes complications; hypoglycemia Resumen : Background and aims: Diabetes mellitus is one of the more prevalent chronic diseases globally, and healthcare expenditures for diabetes care are on the rise. Intensive diabetes treatment has been associated with reducing the risk of chronic complications. However, hypoglycemia, the most common adverse effect, poses a significant risk to individuals' lives and is linked to high costs for healthcare systems. Methods: We conducted a retrospective cross-sectional study to determine direct costs by identifying emergency room visits due to hypoglycemia events using diagnostic codes during January 2017 to June 2019. Direct costs were calculated using billed data from the payer and information on outpatient treatment regimens. Differences in median costs were estimated based on length of stay and type of outpatient treatment. Results: Data from 101 patients and the same number of events were included. Women represented (62.4%) of the patients, the median age was 70 (IQR 59.5-80). Blood glucose levels at admission ranged from 12 mg/dL to 67 mg/dL. Most patients were on insulin for outpatient treatment. The median cost of care per hypoglycemia episode was US $345.35 (IQR US $202-727.8), and the cost per episode was higher in patients treated with regimens that included sulfonylureas. Conclusions: The management of patients admitted to the emergency department with a diagnosis of hypoglycemia places a significant burden on the Colombian healthcare system, primarily due to the associated hospitalization costs. Patients treated with regimens that included sulfonylureas incurred higher costs per episode. Prevention, patient education, and individualized treatment approaches could help alleviate the burden of hypoglycemia on both patients and the healthcare system. Mención de responsabilidad : Rojas-Henao, Natalia A; Garcia-Rivera, Michael; Hernandez-Herrera, Ana C.; Díaz-Giraldo, Juliana; Builes-Montaño, Carlos E. Referencia : Hosp Pract (1995). 2025 Feb;53(1):2439775 DOI (Digital Object Identifier) : 10.1080/21548331.2024.2439775 PMID : 39648816 Derechos de uso : CC BY-NC-ND En línea : https://pubmed.ncbi.nlm.nih.gov/39648816/ Enlace permanente : https://hospitalpablotobon.cloudbiteca.com/pmb/opac_css/index.php?lvl=notice_dis Reserva
Reservar este documento
Ejemplares(1)
Código de barras Número de Ubicación Tipo de medio Ubicación Sección Estado DD002357 AC-2025-040 Archivo digital Producción Científica Artículos científicos Disponible
